- The facility’s novel concept shortens production timelines and enables rapid changes in production capacities across medicines
- Backed by an approximately S$800 million (€558 million) investment, Singapore proudly hosts Asia's first Modulus facility, joining France, where the site was completed in September 2024
Sanofi announced the inauguration of its state-of-the-art manufacturing facility, Modulus, in Singapore, marking a significant milestone in its commitment to delivering innovative healthcare solutions globally. This next-generation facility, located in Tuas Biomedical Park, is highly digitalised and low-carbon, representing a new era in sustainable biopharmaceutical manufacturing. Modulus leverages a ‘industry first’ modular concept that enables flexible manufacturing capabilities to produce next generation vaccines and biological medicines. The inauguration was witnessed by Mr Ong Ye Kung, Singapore’s Minister for Health.
Modulus can be adapted to manufacture up to four vaccines or biopharmaceuticals simultaneously, and can be reconfigured in a matter of days to change over between pre-established technological platforms (live attenuated viral or recombinant protein vaccines, as well as biotechnology derived treatments such as enzymes or monoclonal antibodies), compared with several weeks or months in more conventional plants. The Modulus building is capable of housing the equivalent of 34 standardised production modules, each equipped with interconnected and modular equipment to configure production lines rapidly according to the specific needs of the moment.
The facility will have an adaptable design and scalable production capabilities, strengthening the ability to rapidly develop and produce life-saving therapies, while also holding the potential to significantly bolster pandemic preparedness. By establishing the groundwork for crucial production modules now, Modulus can ensure a swift and targeted response to any future health needs, including potential pandemics.
